OncoSec Medical Incorporated (NASDAQ:ONCS) has been assigned a consensus rating of “Buy” from the six research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $5.33.

A number of equities analysts recently issued reports on the stock. Maxim Group set a $5.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Saturday, June 3rd. ValuEngine upgraded shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. HC Wainwright set a $6.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Monday, June 12th. Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a research report on Wednesday, June 14th. Finally, Dawson James reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th.

COPYRIGHT VIOLATION NOTICE: “OncoSec Medical Incorporated (ONCS) Receives Consensus Rating of “Buy” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/19/oncosec-medical-incorporated-oncs-receives-consensus-rating-of-buy-from-analysts.html.

Shares of OncoSec Medical (NASDAQ:ONCS) opened at 0.92 on Friday. The company has a 50 day moving average of $1.05 and a 200-day moving average of $1.16. The firm’s market cap is $19.47 million. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.06. On average, analysts expect that OncoSec Medical will post ($1.02) EPS for the current year.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.